David W. Mutryn
Thanks, Bruce, and good morning. We had outstanding third quarter results, particularly on the earnings side, driven by solid execution on programs where our government customers increasingly rely on us for efficient handling of greater work output. These results reflect high demand in what are predominantly performance-based arrangements across our contracts. We are raising guidance again this year to not only account for the performance this quarter, but to also capture improved clarity for the upcoming fourth quarter as compared to our thinking on the last call. I'll end my remarks today by sharing early thinking on our expectations for fiscal year 2026, which precedes formal guidance this November. Turning to the results for this third quarter of fiscal year 2025. Maximus reported revenue of $1.35 billion, representing 2.5% year-over-year growth or 4.3% on an organic basis. The U.S. Federal Services and the -- outside the U.S. segments both posted positive organic growth with the U.S. Federal Services segment being the main driver of our consolidated results. The U.S. Services segment delivered results in line with expectations. On the bottom line, the Maximus adjusted EBITDA margin was 14.7%, and adjusted EPS was $2.16 for the quarter, which compares to 13.1% and $1.74, respectively, for the prior year period. This quarter's adjusted EBITDA margin is noticeably above the high end of our target range. This can happen in periods where volumes are stronger than anticipated, thanks to our ability to gain operating leverage on incremental volumes. This leverage is partly the result of our intentional investments in technology, workflow optimization and cost models. Turning to segments. Revenue for the U.S. Federal Services segment increased 11.4% to $761 million. Growth was all organic. We've seen a favorable trend this year where volumes on certain programs, especially in our clinical portfolio, have continued to come in at an elevated run rate. Two years ago, we deliberately invested in added capacity for our clinical work, and that action is now paying dividends as we can scale up to meet the high demand. The operating income margin for the segment in the third quarter was 18.1% as compared to 15.5% in the prior year period. This has set a new high watermark for the segment margin and is a testament to our ability to process elevated levels of work to help our customers. As I mentioned, those elevated levels, which can be unplanned, have a significant effect on the bottom line. For the U.S. Services segment, revenue decreased slightly to $440 million as compared to the prior year period revenue of $472 million. Last year's results were positively impacted by the excess volumes tied to the Medicaid unwinding exercise that was largely completed during the first three quarters of fiscal year 2024. I'd like to acknowledge our success in addressing the unwinding exercise last year, demonstrating how change can promote opportunity. As noted in Bruce's prepared remarks regarding Medicaid and SNAP, we see a similar opportunity for Maximus to rapidly implement policy and legislative changes in support of our customers. The segment's operating income margin for the third quarter was 10.2% compared to 13.0% for the prior year period, which benefited from the excess unwinding volumes. In our view, the segment continues to perform and execute well, and we are focused on driving bottom line improvement headed into next fiscal year when we expect stronger volume levels even before taking into account new market opportunities. Turning to the -- outside the U.S. segment. Revenue decreased to $147 million for the quarter, primarily due to divestitures of multiple employment services businesses in prior periods. The related decrease in revenue was partially offset by organic growth of 7.3% and a slight currency benefit. The segment's operating income margin this quarter was 4.0% and compares to a small loss in the prior year period. We're pleased to report ongoing margin stability in the segment with our goal over the longer term to drive further margin improvement through continued scaling in our present markets. Turning to cash flow items. Cash provided by operating activities was a net outflow of $183 million and free cash flow was a net outflow of $198 million for the quarter. As we saw last quarter and anticipated for this current quarter, we saw a continued cash flow impact by payment delays. Days sales outstanding, or DSO, stepped up again to 96 days for this quarter, which, as I remarked on the last call, we expect to be at peak. It's also well above our historical range and a dynamic that we view as temporary. The payment delays and corresponding higher DSO were primarily driven by two programs, both of which have had positive updates in July that I will take a moment to describe. The first is one of our major U.S. federal programs. We experienced administrative delays that led to a significant increase in our billed AR balance as of June 30. I'm pleased to report that we made meaningful progress and collected more than $300 million related to this major U.S. federal program in July. The second is one of our large state-based programs that we disclosed last quarter. We faced administrative delays tied to a pending contractual extension of our work, which drove an increase to our unbilled AR balance. The positive update is that we received the fully executed extension in July, which prompted $224 million moving from unbilled AR to billed AR. This alone brings our unbilled AR back into a normal range. We anticipate collecting this balance in the fourth quarter. The positive impact of these two items give us confidence in our expectations for a strong fourth quarter of free cash flow as evident in our updated free cash flow guidance. As a reminder, the exact timing of payments can impact reported free cash flow at September 30. We ended the third quarter with total debt of $1.67 billion, resulting in a consolidated net total leverage ratio of 2.1x. High near-term borrowings necessary to cover the higher DSO has increased this ratio, yet we are still at the low end of our target range of 2 to 3x. As a reminder, this ratio is our debt net of allowed cash to consolidated EBITDA for the last 12 months as calculated in accordance with our credit agreement. Going forward, by September 30, we expect the ratio to be comfortably below 2x. The delay in collections has also prompted a more constrained approach to capital allocation, though we believe the recent improvements should enable us to return to our historic approach. This includes seeking potential opportunities on the M&A front and resuming opportunistic share repurchases, utilizing the approximately $66 million remaining under the current $200 million Board of Directors share repurchase authorization. Moving to updated guidance for fiscal year 2025. We're announcing our third consecutive guidance raise, which reflects the exceptional results this quarter as well as an improvement to our outlook for the fourth quarter, thanks to better visibility and less uncertainty compared to our prior thinking. For revenue, the midpoint is increasing by $100 million to a range of $5.375 billion to $5.475 billion. Our implied full year organic growth rate now stands at about 4% over the prior year. Our full year adjusted EBITDA margin guidance for fiscal year 2025 is now approximately 13%, which is a 130 basis point improvement from prior guidance. Our adjusted EPS guidance increases by $1 at the midpoint to range between $7.35 and $7.55 per share. At the midpoint, this reflects year-over-year earnings growth of 22%. With the positive updates to the temporary conditions impacting DSO that I mentioned, we expect a strong finish to the year for free cash flow. We are raising our free cash flow guidance to between $370 million and $390 million. We anticipate DSO falling back to more normal levels next quarter, thanks in part to the now finalized state extension and expected imminent payment. To be clear, our guidance assumes that we will collect the $224 million now billed related to that contract prior to September 30, 2025. A few words on segment operating margin assumptions. The U.S. Federal segment is now forecasted to deliver a margin of approximately 15%. U.S. Services segment is expected to be around 10.5% and outside the U.S. is expected to be between 3% and 5% for the full fiscal year. We expect interest expense of approximately $81 million and our full year tax rate expectation of between 28% and 29% is unchanged. As a reminder, the higher tax rate on a full year basis is tied to the divestiture-related charges in the first quarter. The weighted average shares expectation is also unchanged at 58 million shares on a full year basis. I'll wrap up by sharing our early thinking on our expectations for next fiscal year. As always, this precedes official guidance that we will provide for fiscal year 2026 on the year-end call in November. As context, a year ago, we expressed some caution on fiscal year '25 year-over-year growth given the excess volumes we experienced in fiscal year '24, most notably related to our support of Medicaid programs. Our initial guidance for the year that we provided in November, then adjusted in December for the divestiture was revenue of $5.25 billion and adjusted EPS of $5.85 at the midpoint. Since then, our midpoints have increased by $175 million for revenue and $1.60 for adjusted EPS. We have successfully delivered on higher volumes, particularly in our clinical portfolio in the U.S. Federal segment while also continuing to drive technology and process efficiencies in our cost structure. We are purpose-built to enable us to scale up to meet increasing demand, recognizing that from time to time, components of our business that are volume sensitive can be less easy to precisely predict. As we now look to fiscal year 2026 revenue, it's still early enough to have wide-ranging scenarios. Two areas of focus that are dynamic and create a wider range of scenarios are: first, volume- based contributions that we are not certain will recur at the same level as they have in fiscal year 2025. Second, we are carefully watching for signs of budget constraints and efficiency objectives from customers, which may create opportunities in the long run, but may create near-term headwinds on both the federal and state side. We are staying equally focused on the opportunities in front of us, some of a material nature that could be decided in early fiscal year 2026. This includes proposals sitting in both our in preparation and submitted buckets that, if successful, we anticipate could mildly contribute to fiscal year 2026 and then make stronger contributions to fiscal year 2027. We're also spending time now preparing for opportunities tied to the One Big Beautiful Bill. The exact implementation time line related to these opportunities is uncertain, and therefore, we are prudently forecasting the revenue contribution in fiscal year 2027, although it is possible some portion could come in fiscal year 2026. All that said, at this stage, our preliminary thinking is we have visibility into an anticipated revenue range that is roughly in line with or possibly just slightly below our now raised fiscal year 2025 guidance. There are also scenarios of modest revenue growth, which we believe would result from some combination of less volume moderation on current programs, less impact from budget constraints coming to fruition, and acceleration in revenue from the opportunities we've discussed and updates to the administration's priorities that increase demand for our services. I'll add that our early view also contemplates that in fiscal year 2027, we could see acceleration of organic growth that maps to these opportunities. Stepping back, we believe this demonstrates the business is running in a disciplined manner while we execute on our growth strategy that aligns with our customers' priorities. On the margin front, our current view is we expect next year's adjusted EBITDA margin to remain near the high end of our 10% to 13% target range. This was consistent with the implied guidance for our fourth quarter of about 12.5%. This represents a significant improvement to our fiscal year 2024 adjusted EBITDA margin of 11.6% and our initial fiscal year 2025 guidance of approximately 11%. We believe the sustainability of these higher levels reflects our continuous improvement of productivity and efficiency in our delivery while accommodating our growth investments. The final component to this early view is interest expense, where we anticipate a meaningful reduction next fiscal year. Once more, this represents our early view of our expectations, and we plan to provide formal guidance in November as usual. In conclusion, we're pleased that recent performance shows us meeting our targets that we have set for ourselves and communicated to shareholders in recent years with respect to both our organic revenue growth rate target and our goal to grow earnings faster than revenue. From fiscal year 2022 to today's fiscal year 2025 guidance, organic revenue growth averages 7%, comfortably achieving our mid-single-digit target. In addition, during that same period, we have been able to grow earnings by almost 20% on a compound annual growth rate basis. Looking forward into fiscal year 2026 and beyond, we believe that our organic revenue growth potential remains well intact. And with that, we will open the line for Q&A. Operator?